Viatris Reports 8% Revenue Growth to $3.52 Billion in Q1 2026

Viatris Inc. reported a significant improvement in its financial performance for the first quarter of 2026, with total revenues reaching $3.52 billion, an increase of 8% from $3.25 billion in the same period last year. The company's net sales also rose to $3.51 billion, up from $3.24 billion, driven by new product sales and growth in its Greater China segment. The gross profit for the quarter was $1.16 billion, maintaining a gross margin of 33%, although this was slightly lower than the 36% margin reported in the previous year due to increased costs associated with restructuring and inventory write-offs from a fire at its Nashik manufacturing facility.

The company experienced a notable turnaround in net earnings, reporting a profit of $176.4 million, compared to a loss of $3.04 billion in the prior year, which included a substantial goodwill impairment charge. This shift resulted in earnings per share of $0.15, a significant recovery from a loss of $2.55 per share in the same quarter of 2025. The improved earnings were attributed to a combination of higher sales, reduced operating expenses, and a favorable tax benefit of $423.7 million.

Strategically, Viatris has been active in restructuring its operations, with a plan announced in February 2026 aimed at optimizing its commercial capabilities and reducing its workforce by up to 10%. The company expects to incur pre-tax charges between $700 million and $850 million related to these restructuring activities, which are anticipated to yield annual savings of $600 million to $700 million once fully implemented. Additionally, Viatris completed the sale of its compulsory convertible preferred shares in Biocon Biologics for $815 million, which included both cash and equity shares.

Operationally, Viatris reported a diverse performance across its segments. The Developed Markets segment saw a 7% increase in net sales, while the Greater China segment experienced a 22% rise, driven by strong growth in e-commerce and retail channels. The Emerging Markets segment reported a modest 3% increase, while the JANZ segment faced a slight decline. The company continues to focus on expanding its product portfolio and enhancing its market presence, particularly in emerging markets.

Looking ahead, Viatris remains optimistic about its growth trajectory, emphasizing its commitment to delivering high-quality medicines globally. The company is focused on navigating the challenges posed by regulatory environments and market competition while leveraging its extensive portfolio and operational efficiencies to drive future performance.